Spirapril effects on heart remodeling in patients with mild to moderate arterial hypertension

In total, 62patients with mild to moderate arterial hypertension underwent echocardiography and Doppler cardiography. For 12 weeks, all participants received spirapril, 6 mg/d. Spirapril therapy was associated with reduced left ventricular hypertrophy and pathological heart remodeling type number

DOSE-DEPENDENT EFFECTS OF DIPYRIDAMOLE IN PATIENTS WITH CONGESTIVE HEART FAILURE

We have practiced courses of treatment with dipyridamol (Curantil, Berlin-Chemie), 25 to 225 mg daily, 1-3 months long, in 55 patients with congestive heart failure NYHA III-IV class in conjuction with baseline treatment with ACE inhibitors, prolonged nitrates and diuretics. Treatment efficacy was controlled by thromboelastography, ADP-induced platelet aggregation and bifunctional daily BP and ECG monitoring. A dose-dependent and modulating antiaggregating effect of dipyridamol has been shown in the study. The usage of 225 mg Curantil daily (75 mg 3 times a day) resulted in an antiaggregating action in the first day, however, it was characterized by a higher risk of hypotension with concomitant baseline vasodilating therapy. Considerable antiaggregating effect of 75 mg Curnatil daily (25 mg 3 times a day) and 50-25 mg daily developed by the end of the first and, respectively, second week of treatment; the risk of arterial hypotension was non-significant. We conclude that for long-term prevention in patients with CHF administration of Curantil 75-25 mg daily is preferable. Determining individual sensitivity to the chosen dose (by BP dynamics) is rational before initiating the treatment

THE ROLE OF NO SYNTHESIS CORRECTION IN PREVENTION OF CARDIOVASCULAR HYPERTENSIVE REMODELING

Comparative study of preventive effects of two beta-blocking drugs with different mode of action was performed on SHRSP and WKY rats. Morphological and functional parameters – blood pressure, endothelium-dependent vascular relaxation, plasma level of nitric oxide stable metabolites (nitrite/nitrate), cardiac hyperthrophy and vascular remodeling were monitored during chronic nebivolol and metoprolol injection in parallel groups of rats. Nebivolol, a cardioselective beta-blocker with ancillary nitric oxide modulating and vasodilating properties exhibited more significant and stable influence on the monitored parameters than metoprolol lacking the nitric oxide modulating activity and more effectively prevented cardiovascular remodeling in experimental hypertension

NEW PERSPECTIVES OF DIPYRIDAMOL USAGE IN TREATMENT OF CORONARY HEART DISEASE

There is a great number of coronary patients to whom traditional methods of myocardium revascularization are not indicated. Addition of dipyridamol to traditional antianginal treatment promotes improvement of clinical features of the disease and decreased functional class of angina in coronary patients. The usage of dipyridamol for 3 months was accompanied by increased physical stress tolerance threshold, increased time of physical stress, decreased asynergy areas on echo ate peak stress, suggesting possible angiogenesis in myocardium hypoperfusion areas in the region of stenotic coronary artery